boulevard de Berlaimont 14 – BE-1000 Bruxelles tél. +32 2 221 56 61 numéro d'entreprise: 0203.201.340 RPM Bruxelles www.bnb.be



Bruxelles, le 31 mars 2020

## Annexe 2 à la circulaire NBB\_2020\_008

## **NBB COVID-19 Reporting**

## **Qualitative information**

Name undertaking	[ANSWER]
Name contact person	[ANSWER]
Email contact person	[ANSWER]
Date	[ANSWER]

This document is a living document that should include the latest available information at the company. The document should be updated and reported on a regular basis. It should be submitted via email to <a href="mailto:insurance.supervision@nbb.be">insurance.supervision@nbb.be</a> (with your file manager in copy) on the same day as the regular submissions of the NBB COVID-19 Quantitative reporting.

## Questions referring to information reported in the NBB COVID-19 Quantitative reporting

- 1. Please comment on the main variations of your assets since the last reported period. Which part is explained by market evolutions and which part by an active investment strategy (buying/selling)? Which significant transactions took place since the last reported period?
- 31 March: [ANSWER]
- 7 April: [ANSWER]
- 14 April: [ANSWER]
- 2. Did the average rating or CQS of your government or corporate bond portfolio change since the last reported period? If yes, please specify. On which part of your bond portfolio do you expect a (further) reduction in credit quality?
- 31 March: [ANSWER]
- 7 April: [ANSWER]
- 14 April: [ANSWER]

3.	Please describe the expected evolution of the technical provisions since the last reported period. In case of recalculation of the technical provisions, could you please mention if changes were applied in the used methodology and/or assumptions? If yes, please describe.
4.	Did you recalculate the Best Estimate by discounting the cash flows with an updated RFR curve since the last reported period? Did you update the Volatility Adjustment (VA)? If yes, could you please provide the quantitative impacts on the Best Estimate linked to both the updated RFR curve and the VA separately?
Ev	plution of liquidity
5.	How has your liquidity position been impacted since the start of the market turmoil? Do you expect any liquidity concerns in the (near) future? Did you identify any significant variation in your liquidity position since the last reported period? If yes, please describe.
•••	
6.	Could you please describe the (expected) evolution of <u>premium income</u> since the last reported period? Could you please provide the quantitative impacts?  a) Could you please describe the (expected) evolution of <u>new business</u> since the last reported period?  b) Could you please describe the (expected) evolution of <u>unpaid premiums</u> since the last reported period?
7.	Could you please describe the (expected) evolution of <u>surrenders</u> since the last reported period? Could you please provide the quantitative impacts?
8.	Could you please describe the (expected) evolution of <u>incurred claims</u> due to COVID-19? Could you please provide the quantitative impacts?
Ot	ner impacts
9.	What is the expected full year <u>P&amp;L impact</u> of COVID-19 for 2020? If possible, split between investment result and insurance result and highlight main assumptions.
10.	Could you please describe the (expected) evolution of other (emerging) risks related to COVID-19 such as fraud risk, cyber-attacks, step-in or reputational risk?